BioBAT Brings Bioscience Research To Brooklyn, New York
05/24/2010
"With the development of BioBAT, together with the East River Science Park set to open this fall, we are building 10 times the amount of commercial lab space that's currently available," said New York City Mayor Michael R. Bloomberg.
The City invested $12 million in the project, and the state offered $48 million of funding. Some organizations, such as the International AIDS Vaccine Initiative, are already located there, and will be joined by several others.
"BioBAT's laboratory, office, and manufacturing space on the Brooklyn waterfront is designed for larger companies and offers affordable rents, convenient transportation, and access to all the leading academic research centers in the city," said SUNY Downstate President John C. LaRosa.
The Brooklyn Army Terminal is a 97-acre facility owned by the city and managed by the New York City Economic Development Corporation. BioBAT is a nonprofit corporation that was created to encourage the development of commercial bioscience research, development, and manufacturing in Brooklyn. The architecture firm HOK will design the facility.
Project Announcements
Swiss-Based Temenos Plans Orlando, Florida, Operations
06/23/2025
Phoenix Manufacturing Expands Glasgow, Missouri, Operations
06/23/2025
Otto Aviation Plans Jacksonville, Florida, Manufacturing Operations
06/20/2025
AMI Metals Expands Spokane, Washington, Production Operations
06/20/2025
Newly Weds Foods Plans Dyersburg, Tennessee, Production Operations
06/20/2025
Yaskawa American Expands Franklin, Wisconsin, Headquarters Operations
06/19/2025
Most Read
-
20th Annual Area Development Gold and Silver Shovel Awards
Q2 2025
-
First Person: Joe Capes, CEO, LiquidStack
Q2 2025
-
The Legal Limits of DEI in Incentives Agreements, Hiring, and Contracting
Q2 2025
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Rethinking Life Sciences Site Selection in a Resilient and Dynamic Market
Q2 2025
-
The New Math Behind Mexico and U.S. Manufacturing Decisions
Q2 2025